Site icon pharmaceutical daily

Gritstone bio to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will participate in the following investor conferences. B. Riley Securities’ 3rd Annual Oncology Conference (Fireside Chat)Date and Time: Thursday, January 19, 2023 at 12:30pm ETPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer 2023 BIO CEO & Investor Conference (Panel)Panel Title: Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding PeriodDate and Time: Monday, February 6, 2023 at 2:00pm ETPresenter: Celia Economides, Chief Financial Officer SVB Securities Global Biopharma Conference (Fireside Chat)Date and Time: Thursday, February 16, 2023 at 1:40pm ETPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer Live webcast and/or archived replays will be available via https://ir.gritstonebio.com/investors/events. Archived replays will be accessible for at least 30 days following the corresponding event. About Gritstone bioGritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com Gritstone ContactsInvestors:George E. MacDougallDirector, Investor Relations & Corporate CommunicationsGritstone bio, Inc.ir@gritstone.com Media:Dan Budwick1AB(973) 271-6085dan@1abmedia.com

Exit mobile version